1. Scrip
  2. >>Focus On Asia
  3. >>Japan

GSK Launches Relvar For Asthma In Japan, First ICS/LABA Administered Once A Day

GlaxoSmithKline has launched Relvar and Ellipta (fluticasone furoate/vilanterol) for bronchial asthma in Japan.

GlaxoSmithKline launched Relvar and Ellipta (fluticasone furoate / vilanterol) for bronchial asthma in Japan, the company announced Dec. 9. The drug is the first ICS/LABA combination drug that is effective for 24 hours and is administered just once a day. The prices for the two products are ¥2,816.80 ($27.37) and ¥3,143.90 respectively, with sales expected to peak at ¥24 billion with 1.3 million patients. GSK launched Advair, a twice-a-day ICS/LABA combination in 2007, and sales of that product were at ¥50.3 billion in 2012. Approximately 8% of the Japanese population suffers from bronchial asthma. (Click Here For More – Japanese Language

)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

Torrent Acquires JB Chem In 2025’s Biggest Deal For Indian Pharma

 
• By Vibha Ravi

Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut